Drug intelligence / Profile preview

ACT560

Development stage: Preclinical
Lead developer: Xiamen Tebao Biological Engineering
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

ACT560 is an investigational drug candidate currently in preclinical development by Xiamen Amoytop Biotech for the treatment of chronic hepatitis B. It is part of the company's immunology-focused research and development pipeline, which aims to develop innovative therapies for achieving a functional cure in patients with chronic hepatitis B virus (HBV) infection. While specific details regarding its molecular structure, target, and mechanism of action have not been publicly disclosed, ACT560 represents one of several proprietary approaches Amoytop is pursuing in the field of antiviral immunotherapy.

Beyond the preview

Go deeper on ACT560.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT560.

Explore the full profile